Abstract

Screening the active compounds of herbal medicines is of importance to modern drug discovery. In this work, an integrative strategy was established to discover the effective compounds and their therapeutic targets using Phellodendri Amurensis cortex (PAC) aimed at inhibiting prostate cancer as a case study. We found that PAC could be inhibited the growth of xenograft tumours of prostate cancer. Global constituents and serum metabolites were analysed by UPLC-MS based on the established chinmedomics analysis method, a total of 54 peaks in the spectrum of PAC were characterised in vitro and 38 peaks were characterised in vivo. Among the 38 compounds characterised in vivo, 29 prototype components were absorbed in serum and nine metabolites were identified in vivo. Thirty-four metabolic biomarkers were related to prostate cancer, and PAC could observably reverse these metabolic biomarkers to their normal level and regulate the disturbed metabolic profile to a healthy state. A chinmedomics approach showed that ten absorbed constituents, as effective compounds, were associated with the therapeutic effect of PAC. In combination with bioactivity assays, the action targets were also predicted and discovered. As an illustrative case study, the strategy was successfully applied to high-throughput screening of active compounds from herbal medicine.

Highlights

  • Prostate cancer is one of the most common malignant tumours of the urogenital system in elderly males, especially in European and American men[1,2]

  • We investigated the therapeutic efficiency of Phellodendri Amurensis cortex (PAC) in inhibiting the growth of xenograft tumours after the subcutaneous inoculation of 22RV1 human prostate cancer cells into male BALB/c-nude mice

  • We established a blood metabolomics method based on UPLC-G2-Si-High Definition TOF Mass (HDMS) and combined this with the observation of xenograft tumour growth and its histopathology: comprehensive analysis of the changes in metabolomic profiling in prostate cancer model mice and evaluate the therapeutic effect of PAC against prostate cancer

Read more

Summary

Results

PCA results indicated biochemical perturbation in vivo after injecting the 22RV1 human prostate cancer cells into model group mice. Hierarchical cluster analysis showed that the metabolic profile in the treatment group was close to that of the control group, it was indicated that PAC had therapeutic efficacy, the dendrogram and heatmap are shown in Fig. 6E and F. Through establishing a correlation model between the metabolic biomarkers and the chemical compounds, the relevant parameters were: 0.9

Discussion
Author Contributions
Additional Information
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.